There are over 7,000 rare diseases and only 10% have FDA-approved treatments —the process of developing therapies for rare diseases involves special challenges and considerations. To meet these challenges, NORD and the Critical Path Institute (C-Path) are working together on a new initiative called the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), bringing together data from different sources and providing tools for streamlining the steps of research and development. In video #2 of NORD and C-Path's three-part video series, “Accelerating Rare Disease Drug Development,” we examine the challenges of developing therapies for rare diseases at each step of the drug development process.
Learn more: rarediseases.org/rdca-dap/
